ScholarWorks - Idaho Conference on Undergraduate Research: Inhibition of Cellular Growth and DNA Replication by Anthracycline Analogs
 

Inhibition of Cellular Growth and DNA Replication by Anthracycline Analogs

Faculty Mentor Information

Phil Moon, Dr. Ken Cornell Ph.D., and Dr. Don Warner Ph.D.

Presentation Date

7-2016

Abstract

Doxorubicin (DOX) is a leading drug used to treat soft tissue sarcomas (STS), but has shown a limited effectiveness because of serious drug-induced cardiotoxicity. Two new DOX derivatives, GPX-150 and GPX-160, have been developed to overcome this toxicity. The current study involves determining the in vitro anti-proliferative effects of these compounds against human cancer and normal cells. Based on the in vitro cell viability data, the GPX-series compounds show promise as anti-cancer agents. One of the known DOX mechanisms of action is interference with DNA replication through inhibition of DNA topoisomerase II and gyrase enzymes. To examine whether the GPX-series compounds also inhibit these enzymes, topoisomerase and gyrase activity assays were performed and analyzed by gel electrophoresis. The results indicate that the GPX-series compounds also affect topoisomerase and gyrase activity at low micromolar concentrations.

Comments

Poster #Th17

This document is currently not available here.

Share

COinS
 

Inhibition of Cellular Growth and DNA Replication by Anthracycline Analogs

Doxorubicin (DOX) is a leading drug used to treat soft tissue sarcomas (STS), but has shown a limited effectiveness because of serious drug-induced cardiotoxicity. Two new DOX derivatives, GPX-150 and GPX-160, have been developed to overcome this toxicity. The current study involves determining the in vitro anti-proliferative effects of these compounds against human cancer and normal cells. Based on the in vitro cell viability data, the GPX-series compounds show promise as anti-cancer agents. One of the known DOX mechanisms of action is interference with DNA replication through inhibition of DNA topoisomerase II and gyrase enzymes. To examine whether the GPX-series compounds also inhibit these enzymes, topoisomerase and gyrase activity assays were performed and analyzed by gel electrophoresis. The results indicate that the GPX-series compounds also affect topoisomerase and gyrase activity at low micromolar concentrations.